METASTATIK ONKOGINEKOLOGIK RAKDA MIOSTEATOZ: MUAMMONING HOZIRGI HOLATI
##article.subject##:
miosteatoz, onkoginekologik rak, metastazlar, kimyoterapiya toksikligi, omon qolish, kompyuter tomografiya##article.abstract##
Miosteatoz — skelet mushaklarining yog‘ bilan infiltratsiyalanishi — onkologik bemorlarda tana kompozitsiyasi buzilishlarining muhim tarkibiy qismi hisoblanadi. Metastatik onkoginekologik rakda ushbu holat an’anaviy antropometrik ko‘rsatkichlarga tayanilganda ko‘pincha yetarli darajada baholanmaydi, garchi u davolashni ko‘tarish darajasi va kasallik prognoziga sezilarli ta’sir ko‘rsatsa ham. Ushbu sharhda miosteatozning patofiziologik mexanizmlari, kimyoterapiya toksikligi bilan bog‘liqligi hamda umumiy va kasalliksiz omon qolishga ta’siri bo‘yicha zamonaviy ilmiy ma’lumotlar umumlashtirilgan. Kompyuter tomografiya asosida aniqlangan mushak zichligining pasayishi, ayniqsa tana massasi indeksi saqlangan yoki yuqori bo‘lgan bemorlarda, noqulay onkologik natijalarning mustaqil prognostik omili ekanligi ko‘rsatilgan. Miosteatozni baholashni ko‘p omilli xavf stratifikatsiyasi modellari tarkibiga kiritish metastatik onkoginekologik rak bilan kasallangan bemorlarni shaxsiylashtirilgan boshqarishni takomillashtirish imkonini beradi.
Библиографические ссылки
Amini, B., Boyle, S. P., Boutin, R. D., & Lenchik, L. (2019). Assessment of muscle density by computed tomography and magnetic resonance imaging in oncologic patients: Association with outcomes. Skeletal Radiology, 48(12), 1877–1885. https://doi.org/10.1007/s00256-019-03225-0
Baracos, V. E., Arribas, L., Sarlo, C., & Prado, C. M. (2018). Myosteatosis: A marker of muscle quality and predictor of survival in cancer patients. The Lancet Oncology, 19(9), e402–e412. https://doi.org/10.1016/S1470-2045(18)30340-3
Fearon, K., Strasser, F., Anker, S. D., Bosaeus, I., Bruera, E., Fainsinger, R. L., … Baracos, V. E. (2011). Definition and classification of cancer cachexia: An international consensus. The Lancet Oncology, 12(5), 489–495. https://doi.org/10.1016/S1470-2045(10)70218-7
Goodpaster, B. H., Theriault, R., Watkins, S. C., & Kelley, D. E. (2001). Intramuscular lipid content is increased in obesity and decreased by weight loss. Metabolism, 49(4), 467–472. https://doi.org/10.1016/S0026-0495(00)80010-4
Lokireddy, S., Wijesoma, I. W., Bonala, S., Wei, M., Sze, S. K., McFarlane, C., … Sharma, M. (2012). Myostatin induces degradation of sarcomeric proteins through an autophagy-dependent mechanism. American Journal of Physiology – Cell Physiology, 303(7), C650–C661. https://doi.org/10.1152/ajpcell.00114.2012
Martin, L., Birdsell, L., Macdonald, N., Reiman, T., Clandinin, M. T., McCargar, L. J., … Baracos, V. E. (2013). Cancer cachexia in the age of obesity: Skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. Journal of Clinical Oncology, 31(12), 1539–1547. https://doi.org/10.1200/JCO.2012.45.2722
Mourtzakis, M., Prado, C. M., Lieffers, J. R., Reiman, T., McCargar, L. J., & Baracos, V. E. (2008). A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Applied Physiology, Nutrition, and Metabolism, 33(5), 997–1006. https://doi.org/10.1139/H08-075
Murphy, K. T., Lynch, G. S., & Ryall, J. G. (2010). Interleukin-6 signalling and skeletal muscle atrophy in cancer cachexia. Journal of Cachexia, Sarcopenia and Muscle, 1(1), 47–54. https://doi.org/10.1007/s13539-010-0007-1
Prado, C. M., Baracos, V. E., McCargar, L. J., Reiman, T., Mourtzakis, M., Tonkin, K., … Sawyer, M. B. (2007). Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clinical Cancer Research, 13(11), 3264–3268. https://doi.org/10.1158/1078-0432.CCR-06-3067
Prado, C. M., Lieffers, J. R., McCargar, L. J., Reiman, T., Sawyer, M. B., Martin, L., & Baracos, V. E. (2008). Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts. The Lancet Oncology, 9(7), 629–635. https://doi.org/10.1016/S1470-2045(08)70153-0
Prado, C. M., Wells, J. C. K., Smith, S. R., Stephan, B. C. M., & Siervo, M. (2012). Sarcopenic obesity: A critical appraisal of the current evidence. Clinical Nutrition, 31(5), 583–601. https://doi.org/10.1016/j.clnu.2012.06.010
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023). Cancer statistics, 2023. CA: A Cancer Journal for Clinicians, 73(1), 17–48. https://doi.org/10.3322/caac.21763
Shavkatovna S. S., Makhammatkulovich R. N. FEATURES OF SARCOPENIA IN CANCER PATIENTS //EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE. – 2024. – Т. 4. – №. 8. – С. 286-292.
Shavkatovna S. S., Makhammatkulovich R. N., Ugli M. S. T. ASPECTS OF SARCOPENIA SYNDROME IN ONCOLOGICAL PRACTICE: DIAGNOSIS AND TREATMENT //The American Journal of Medical Sciences and Pharmaceutical Research. – 2024. – Т. 6. – №. 02. – С. 16-25.
Makhammatkulovich, RAKHIMOV Nodir, et al. "ПАТОГЕНЕТИЧЕСКИЕ АСПЕКТЫ РАКОВОЙ АНОРЕКСИИ." JOURNAL OF BIOMEDICINE AND PRACTICE 8.4 (2023). Makhammatkulovich R. N. et al. PRACTICAL RECOMMENDATIONS FOR NUTRITIONAL SUPPORT FOR CERVICAL CANCER //JOURNAL OF BIOMEDICINE AND PRACTICE. – 2023. – Т. 8. – №. 2.
